2-chloro-3-((phenylsulfonyl)methyl)quinoxaline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-chloro-3-((phenylsulfonyl)methyl)quinoxaline
• 英文别名: 2-Chloro-3-(phenylsulfonylmethyl)quinoxaline；2-(benzenesulfonylmethyl)-3-chloroquinoxaline
• 化学式: C₁₅H₁₁ClN₂O₂S
• 分子量: 318.784
• InChiKey: AMNQYONRCBZMGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  68.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氯-3-甲基喹喔啉 、 sodium benzenesulfonate 在 过氧化苯甲酸叔丁酯 、 四丁基碘化铵 作用下， 以 水 为溶剂， 反应 10.0h， 以65%的产率得到2-chloro-3-((phenylsulfonyl)methyl)quinoxaline
  参考文献：
  名称：

  TBAI在水中合成C（sp 3）-H键磺酰化 合成2-巯基甲基氮杂氮杂

  摘要：

  已经开发了碘化四丁铵（TBAI）催化的2-巯基甲基喹诺酮合成方法。使用水作为溶剂，可以高收率获得优异的2-巯基甲基喹诺酮类化合物。此外，水和TBAI可以重复使用五次，而相应产品的收率却没有显着降低。

  DOI：

  10.1007/s11164-018-3573-z

文献信息

• METHODS AND COMPOSITIONS FOR SCREENING AND TREATMENT OF DISORDERS OF BLOOD GLUCOSE REGULATION
  申请人：Perlegen Sciences, Inc.

  公开号：EP1931805A2

  公开（公告）日：2008-06-18
• PHOTO-CROSSLINKED NUCLEIC ACID HYDROGELS
  申请人：Cornell University

  公开号：EP2324045A2

  公开（公告）日：2011-05-25
• Nucleic Acid-Based Matrixes
  申请人：LUO Dan

  公开号：US20070148246A1

  公开（公告）日：2007-06-28

  Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include delivery of biologically active agents, cell and tissue culture, and cell-free protein synthesis.
• Nucleic Acid-Based Matrixes for Protein Production
  申请人：LUO Dan

  公开号：US20070117177A1

  公开（公告）日：2007-05-24

  Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. Methods of utilizing such biomaterials include cell-free protein synthesis.
• Methods and compositions for screening and treatment of disorders of blood glucose regulation
  申请人：McCamish Mark A.

  公开号：US20080280955A1

  公开（公告）日：2008-11-13

  In one aspect, the invention provides a method of screening and, optionally, treatment of an individual suffering from an insulin resistance disorder by screening an individual in need of treatment for an insulin resistance disorder for one or more genetic variations indicating a predisposition to a response to an insulin sensitizer; and, optionally, administering or not administering an insulin sensitizer to the individual based on the results of the screening. The insulin sensitizer for which the individual is screened and the insulin sensitizer that is administered or not administered may be the same or different. In another aspect, the invention provides methods comprising identifying one or more genetic variations, e.g., one or more single nucleotide polymorphisms, that at least partly differentiate between a subset of a plurality of individuals who experience a response when administered an insulin sensitizer, and a subset of said plurality of individuals who do not experience a response when administered the insulin sensitizer. The invention also provides nucleic acids, polypeptides, antibodies, kits, and business methods associated with these screening and association methods.